CASE DESCRIPTION: A French Caucasian man aged 39 with HIV infection was treated with abacavir/lamivudine and ritonavir/lopinavir. The patient (normal renal and liver functions) was diagnosed with a Burkitt lymphoma for which he was treated with cyclophosphamide day 1 to 5; doxorubicin day 1; methotrexate day 10; and vincristine day 1 and 8. At day 12, he suffered from abdominal pain associated with constipation. Paralytic ileus was diagnosed by study imaging. Ileus lasted 10 days necessitating parenteral feeding. Later on, a further cycle of chemotherapy with etoposide replacing vincristine was given and was well tolerated. CONCLUSION: We speculate that an interaction between ritonavir/lopinavir and vincristine was responsible for this severe toxicity. Vincristine is transported by P-gp and is metabolized via CYP3A5. Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor. Lopinavir is also a P-gp inhibitor. Ritonavir and lopinavir might have delayed vincristine elimination. Clinicians should be aware of this possible interaction.
CASE DESCRIPTION: A French Caucasian man aged 39 with HIV infection was treated with abacavir/lamivudine and ritonavir/lopinavir. The patient (normal renal and liver functions) was diagnosed with a Burkitt lymphoma for which he was treated with cyclophosphamide day 1 to 5; doxorubicin day 1; methotrexate day 10; and vincristine day 1 and 8. At day 12, he suffered from abdominal pain associated with constipation. Paralytic ileus was diagnosed by study imaging. Ileus lasted 10 days necessitating parenteral feeding. Later on, a further cycle of chemotherapy with etoposide replacing vincristine was given and was well tolerated. CONCLUSION: We speculate that an interaction between ritonavir/lopinavir and vincristine was responsible for this severe toxicity. Vincristine is transported by P-gp and is metabolized via CYP3A5. Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor. Lopinavir is also a P-gp inhibitor. Ritonavir and lopinavir might have delayed vincristine elimination. Clinicians should be aware of this possible interaction.
Authors: S Quaranta; D Chevalier; D Allorge; J M Lo-Guidice; F Migot-Nabias; A Kenani; M Imbenotte; F Broly; B Lacarelle; M Lhermitte Journal: Xenobiotica Date: 2006-12 Impact factor: 1.908
Authors: E Vaccher; M Spina; G di Gennaro; R Talamini; G Nasti; O Schioppa; G Vultaggio; U Tirelli Journal: Cancer Date: 2001-01-01 Impact factor: 6.860
Authors: Jennifer B Dennison; Palaniappan Kulanthaivel; Robert J Barbuch; Jamie L Renbarger; William J Ehlhardt; Stephen D Hall Journal: Drug Metab Dispos Date: 2006-05-05 Impact factor: 3.922
Authors: Jennifer B Dennison; Michael A Mohutsky; Robert J Barbuch; Steven A Wrighton; Stephen D Hall Journal: J Pharmacol Exp Ther Date: 2008-07-23 Impact factor: 4.030
Authors: Gema Vera; Ana E López-Pérez; José A Uranga; Rocío Girón; Ma Isabel Martín-Fontelles; Raquel Abalo Journal: Front Pharmacol Date: 2017-02-06 Impact factor: 5.810